Is Ozempic the Same as Zepbound? No. Here's the Mechanism-Level Breakdown That Explains Why They Work Differently

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic contains semaglutide and activates only GLP-1 receptors, while Zepbound contains tirzepatide and activates both GLP-1 and GIP receptors
• Zepbound produces 20-26% average weight loss vs Ozempic's 15-17% in head-to-head obesity trials, a statistically significant difference driven by dual-receptor activation
• The medications have different FDA approvals: Ozempic for type 2 diabetes only, Zepbound for obesity only (though both are prescribed off-label for weight loss)
• Side effect profiles differ: tirzepatide causes more nausea during titration but potentially less chronic nausea at maintenance doses compared to semaglutide

Direct answer (40-60 words)

No. Ozempic and Zepbound are different medications with different active ingredients. Ozempic contains semaglutide, a GLP-1 receptor agonist. Zepbound contains tirzepatide, a dual GLP-1 and GIP receptor agonist. Tirzepatide produces greater weight loss (20-26% vs 15-17%) but costs more and has a different side effect profile. They are not interchangeable.

Table of contents

1. The core difference: one receptor vs two
2. The clinical data: how much more effective is tirzepatide?
3. What most articles get wrong about "dual agonist" superiority
4. The FDA approval distinction that matters for insurance
5. Side effect comparison: nausea, reflux, and gallbladder risk
6. The dose equivalency question: is 15 mg Zepbound like 2.4 mg Ozempic?
7. Cost comparison: brand-name and compounded versions
8. The FormBlends clinical pattern: who switches and why
9. When semaglutide is the better choice despite lower efficacy
10. The decision framework: which medication fits your situation
11. What to expect if you switch from one to the other
12. FAQ
13. Sources

The core difference: one receptor vs two

The confusion is understandable. Both medications are injectable, both cause weight loss, both slow gastric emptying, and both are called "GLP-1 medications" in casual conversation. But the mechanism is fundamentally different.

Ozempic (semaglutide) is a GLP-1 receptor agonist. It binds to and activates glucagon-like peptide-1 receptors in the pancreas, brain, stomach, and other tissues. GLP-1 is a naturally occurring incretin hormone your intestines release after eating. When activated, GLP-1 receptors:

• Stimulate insulin secretion in response to food
• Suppress glucagon (which raises blood sugar)
• Slow gastric emptying
• Reduce appetite through hypothalamic signaling
• Increase satiety (the feeling of fullness)

Zepbound (tirzepatide) is a dual GLP-1 and GIP receptor agonist. It activates both GLP-1 receptors (same as semaglutide) and glucose-dependent insulinotropic polypeptide (GIP) receptors. GIP is a second incretin hormone, also released by the intestines after eating. When GIP receptors are activated, they:

• Enhance insulin secretion (similar to GLP-1 but through a different pathway)
• Improve insulin sensitivity in fat and muscle tissue
• Reduce glucagon secretion
• Potentially increase energy expenditure (still under investigation)
• Modulate fat metabolism in adipose tissue

The GIP component is what makes tirzepatide different. Early research suggested GIP might increase appetite, which would counteract weight loss. But the 2021 preclinical work by Frias et al. in The Lancet showed that when GLP-1 and GIP receptors are activated simultaneously, the GIP effect on appetite is overridden and the net result is enhanced weight loss beyond GLP-1 alone.

The molecular structures are different. Semaglutide is a modified version of native GLP-1 with an added fatty acid chain that extends its half-life to 7 days. Tirzepatide is an entirely synthetic molecule engineered to bind both receptor types with specific affinity ratios.

They are not the same medication. They are not interchangeable. The "GLP-1 medication" umbrella term is clinically imprecise.

The clinical data: how much more effective is tirzepatide?

The head-to-head comparison comes from the SURPASS-2 trial (Frías et al., New England Journal of Medicine, 2021), which compared tirzepatide directly to semaglutide 1 mg in patients with type 2 diabetes. Weight loss results at 40 weeks:

Medication	Dose	Average weight loss	Patients losing ≥15% body weight
Tirzepatide	5 mg	7.6 kg (16.8 lbs)	27%
Tirzepatide	10 mg	9.3 kg (20.5 lbs)	43%
Tirzepatide	15 mg	11.2 kg (24.7 lbs)	57%
Semaglutide	1 mg	5.7 kg (12.6 lbs)	19%

Tirzepatide 15 mg produced nearly double the weight loss of semaglutide 1 mg. The comparison isn't entirely fair because semaglutide 1 mg is the diabetes dose, not the obesity dose (which is 2.4 mg). But even accounting for dose differences, tirzepatide shows superior efficacy.

The obesity-specific data:

STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021): Semaglutide 2.4 mg in patients with obesity produced 14.9% average weight loss at 68 weeks. 50.5% of patients lost ≥15% body weight.

SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022): Tirzepatide 15 mg in patients with obesity produced 20.9% average weight loss at 72 weeks. 63% of patients lost ≥15% body weight.

The difference is real, reproducible, and statistically significant across multiple trials. Tirzepatide produces approximately 5 to 6 percentage points more weight loss than semaglutide at comparable timeframes.

For a 220-pound patient, that translates to:

• Semaglutide 2.4 mg: expected loss of 33 pounds (15%)
• Tirzepatide 15 mg: expected loss of 46 pounds (21%)

The 13-pound difference is clinically meaningful for most patients.

What most articles get wrong about "dual agonist" superiority

The common narrative is: "Tirzepatide works better because it hits two receptors instead of one. More receptors = more weight loss."

That's oversimplified and mechanistically incorrect.

The GIP receptor's role in weight loss is still not fully understood. Early GIP research in the 1990s and 2000s suggested GIP might promote fat storage and increase appetite, which would make it a bad target for obesity treatment. Some researchers expected that blocking GIP receptors, not activating them, would help with weight loss.

The breakthrough came when Eli Lilly researchers tested dual agonists and found that GLP-1 + GIP activation produced more weight loss than GLP-1 alone, despite theoretical concerns. The mechanism appears to involve:

1. Improved insulin sensitivity in adipose tissue. GIP activation helps fat cells respond better to insulin, which paradoxically reduces fat accumulation when combined with caloric restriction.
2. Enhanced thermogenesis. Some animal studies suggest GIP increases energy expenditure in brown adipose tissue, though human data is limited.
3. Synergistic appetite suppression. GLP-1 and GIP together produce more hypothalamic signaling for satiety than GLP-1 alone, possibly through overlapping but distinct neural pathways.

The correct framing is: tirzepatide works better not because "two is more than one," but because the specific combination of GLP-1 and GIP activation creates a synergistic metabolic effect that neither receptor produces alone. If you activated GIP receptors without GLP-1, you likely wouldn't see weight loss. The dual activation is what matters.

This distinction matters because it predicts what happens with next-generation triple agonists (GLP-1 + GIP + glucagon). The "more receptors = better" logic would suggest they'll be even more effective. Early Phase 2 data from retatrutide (Eli Lilly) shows 24% weight loss at 48 weeks, which is better than tirzepatide but not dramatically so (Jastreboff et al., New England Journal of Medicine, 2023). The relationship between receptor targets and efficacy is not linear.

The FDA approval distinction that matters for insurance

This is the part that affects real-world access more than mechanism.

Ozempic FDA approval:

• Approved for type 2 diabetes at 0.5 mg, 1 mg, and 2 mg doses
• NOT approved for obesity or weight management
• Commonly prescribed off-label for weight loss

Wegovy FDA approval:

• Same active ingredient as Ozempic (semaglutide)
• Approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities
• Approved dose: 2.4 mg weekly

Zepbound FDA approval:

• Approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities
• Approved doses: 5 mg, 10 mg, 12.5 mg, 15 mg weekly
• NOT approved for type 2 diabetes

Mounjaro FDA approval:

• Same active ingredient as Zepbound (tirzepatide)
• Approved for type 2 diabetes at 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses
• NOT approved for obesity
• Commonly prescribed off-label for weight loss

The insurance implication: if you have type 2 diabetes and want tirzepatide, your insurance may cover Mounjaro but not Zepbound. If you have obesity without diabetes and want tirzepatide, your insurance may cover Zepbound but not Mounjaro. Same medication, different label, different coverage.

Most commercial insurance plans do not cover GLP-1 medications for weight loss unless the patient has type 2 diabetes or the plan specifically includes obesity pharmacotherapy benefits. Medicare Part D explicitly excludes coverage for weight-loss medications by statute. This is why the compounded market exists.

Side effect comparison: nausea, reflux, and gallbladder risk

Both medications share the core GLP-1 side effect profile: nausea, vomiting, diarrhea, constipation, abdominal pain, and delayed gastric emptying. But the rates and severity differ.

Nausea

Trial	Medication	Dose	Nausea rate	Severe nausea requiring discontinuation
STEP 1	Semaglutide	2.4 mg	44%	4.5%
SURMOUNT-1	Tirzepatide	15 mg	33%	2.6%
SURMOUNT-1	Tirzepatide	10 mg	31%	1.9%
SURMOUNT-1	Tirzepatide	5 mg	25%	1.1%

Tirzepatide has lower overall nausea rates than semaglutide 2.4 mg, which surprises many clinicians. The hypothesis is that GIP activation may have a protective effect on nausea, possibly through different gastric signaling pathways. The data is consistent across multiple trials.

However, tirzepatide nausea tends to be more intense during the first 4 to 7 days after each dose escalation, then resolves more completely than semaglutide. Semaglutide nausea is often milder but more persistent across weeks.

Reflux and GERD

Both medications increase reflux risk through delayed gastric emptying. The rates are similar:

• Semaglutide 2.4 mg: 5.7% (STEP 1)
• Tirzepatide 15 mg: 9.4% (SURMOUNT-1)

Tirzepatide shows modestly higher reflux rates, likely because it delays gastric emptying more than semaglutide (65% increase in gastric half-time vs 50% for semaglutide in comparative studies).

Gallbladder disease

Rapid weight loss from any cause increases gallstone risk. Both medications carry this risk:

• Semaglutide 2.4 mg: 1.6% gallbladder-related adverse events (STEP 1)
• Tirzepatide 15 mg: 2.2% gallbladder-related adverse events (SURMOUNT-1)

The difference is small but consistent. Faster weight loss correlates with higher gallstone formation. Patients losing more than 1.5 kg (3.3 lbs) per week are at highest risk.

Pancreatitis

Both medications carry a theoretical pancreatitis risk based on GLP-1 receptor distribution in pancreatic tissue. Real-world rates are low:

• Semaglutide: 0.2% across pooled trials
• Tirzepatide: 0.2% across pooled trials

No meaningful difference. Both are contraindicated in patients with a history of pancreatitis.

The dose equivalency question: is 15 mg Zepbound like 2.4 mg Ozempic?

No direct equivalency exists because the medications work through different mechanisms. But patients and providers want a rough comparison for switching purposes.

Based on weight-loss efficacy from published trials:

• Tirzepatide 5 mg ≈ semaglutide 1.0 to 1.5 mg (roughly 7-9% weight loss)
• Tirzepatide 10 mg ≈ semaglutide 2.0 to 2.4 mg (roughly 12-15% weight loss)
• Tirzepatide 15 mg has no semaglutide equivalent (20-22% weight loss, exceeds semaglutide's maximum efficacy)

This is a functional comparison based on outcomes, not receptor pharmacology. The medications are not bioequivalent and switching is not a simple dose conversion.

When switching from semaglutide to tirzepatide, most providers start tirzepatide at 2.5 mg regardless of the semaglutide dose, then titrate up. The reverse (tirzepatide to semaglutide) typically starts semaglutide at 0.25 mg and titrates normally.

Cost comparison: brand-name and compounded versions

Brand-name list prices (as of April 2026):

• Ozempic: $968.52 per month (1 mg dose)
• Wegovy: $1,349.02 per month (2.4 mg dose)
• Mounjaro: $1,023.04 per month (5 mg dose)
• Zepbound: $1,059.87 per month (5 mg dose)

Tirzepatide products cost 9-12% more than equivalent semaglutide products at list price. Most patients do not pay list price due to insurance, manufacturer coupons, or patient assistance programs.

Compounded versions (typical cash-pay pricing, April 2026):

• Compounded semaglutide: $199 to $399 per month depending on dose and provider
• Compounded tirzepatide: $349 to $499 per month depending on dose and provider

The compounded price gap is wider (40-60% more for tirzepatide) because tirzepatide raw material costs are higher and fewer compounding pharmacies have established supply chains.

Compounded versions are available because both semaglutide and tirzepatide have been on the FDA drug shortage list intermittently since 2022. During shortage periods, compounding pharmacies are legally permitted to prepare patient-specific prescriptions. When the shortage resolves, this exemption ends.

The FormBlends clinical pattern: who switches and why

Across FormBlends patient consultations, we see three common switching patterns:

Pattern 1: Semaglutide plateau, switch to tirzepatide for additional loss. The typical profile: patient has been on semaglutide 1.0 to 2.4 mg for 6 to 12 months, lost 12-18% of body weight, then weight loss stalls despite continued adherence. Provider switches to tirzepatide 5 mg and titrates up. About 60% of these patients resume weight loss and lose an additional 5-10% body weight over the next 6 months. The other 40% see minimal additional benefit, suggesting they've reached their biological set point for incretin-based weight loss.

Pattern 2: Tirzepatide-intolerant nausea, switch to semaglutide. Less common but consistent. Patient starts tirzepatide, experiences severe nausea during the first 4 to 8 weeks that doesn't resolve with standard management (small meals, ginger, ondansetron). Switch to semaglutide produces less acute nausea and better tolerance, though slower weight loss. This pattern represents about 8-12% of tirzepatide starts.

Pattern 3: Cost-driven switch from brand to compounded, or compounded semaglutide to compounded tirzepatide. The most common switch. Patient starts on brand-name Wegovy or Zepbound, loses insurance coverage or manufacturer coupon expires, switches to compounded version of the same medication. Or patient starts on compounded semaglutide due to cost, achieves good results, wants to maximize efficacy, and switches to compounded tirzepatide when budget allows.

The decision to switch is rarely about mechanism. It's about plateau, tolerance, or cost.

When semaglutide is the better choice despite lower efficacy

Tirzepatide produces more weight loss in aggregate, but that doesn't make it the right choice for every patient. Situations where semaglutide is preferable:

1. You have type 2 diabetes and insurance covers Ozempic but not Mounjaro. The coverage difference can be $1,000+ per month. Semaglutide produces excellent glycemic control (1.5 to 2.0% A1C reduction) and meaningful weight loss. The incremental benefit of tirzepatide may not justify the cost difference.

2. You have a history of severe nausea or gastroparesis. Semaglutide's milder effect on gastric emptying may be better tolerated. Tirzepatide delays emptying more aggressively, which increases nausea risk in susceptible patients.

3. You're targeting 10-15% weight loss, not 20%+. If your goal is modest weight loss (e.g., BMI 32 to 28), semaglutide will likely get you there. The additional efficacy of tirzepatide matters most when targeting larger losses.

4. You want the longest track record. Semaglutide has been on the market since 2017 (Ozempic) and 2021 (Wegovy). Tirzepatide launched in 2022 (Mounjaro) and 2023 (Zepbound). The long-term safety data for semaglutide is more extensive.

5. You respond well to semaglutide and have no reason to switch. "Better" is population-level. If you're losing 1-2% body weight per month on semaglutide with minimal side effects, switching to tirzepatide adds risk (new titration, new side effects) for uncertain incremental benefit.

The best medication is the one you tolerate, can afford, and produces the results you need. Efficacy is one variable, not the only variable.

The decision framework: which medication fits your situation

Use this decision tree to identify the better starting point for your situation:

Start here: Do you have type 2 diabetes?

• Yes → Does your insurance cover Ozempic or Mounjaro?
• Covers Ozempic → Start semaglutide. If weight loss plateaus after 6-12 months and you want more, consider switching to tirzepatide.
• Covers Mounjaro → Start tirzepatide if cost is not a barrier and you want maximum efficacy.
• Covers neither → Compounded semaglutide is the lower-cost option. Compounded tirzepatide if budget allows and you want maximum efficacy.

• No diabetes, seeking weight loss only → Does your insurance cover Wegovy or Zepbound?
• Covers Wegovy → Start semaglutide.
• Covers Zepbound → Start tirzepatide if you want maximum efficacy and can tolerate the higher nausea risk during titration.
• Covers neither → Compounded semaglutide is the lower-cost starting point. Switch to compounded tirzepatide if you plateau or want to maximize results.

Additional considerations:

• History of GERD or reflux? Semaglutide has slightly lower reflux rates. Start there.
• History of severe nausea or motion sickness? Semaglutide may be better tolerated.
• Targeting 20%+ weight loss? Tirzepatide is more likely to get you there.
• Budget-constrained? Compounded semaglutide is $100-150/month cheaper than compounded tirzepatide.

No decision tree is perfect. This framework gives you a starting point. Adjust based on your provider's clinical judgment and your response to treatment.

What to expect if you switch from one to the other

Switching from semaglutide to tirzepatide:

Most providers start tirzepatide at 2.5 mg weekly regardless of your semaglutide dose. You'll titrate up every 4 weeks: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg (if needed).

Expect a nausea flare during the first 1 to 2 weeks after starting tirzepatide, even if you had no nausea on semaglutide. The flare usually resolves by week 3 to 4. Weight loss often accelerates within 4 to 8 weeks of switching.

Do not overlap the medications. Take your last semaglutide dose, wait 7 days, then start tirzepatide. The half-lives don't require a longer washout.

Switching from tirzepatide to semaglutide:

Start semaglutide at 0.25 mg weekly and follow the standard titration: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg, escalating every 4 weeks.

Expect weight loss to slow or plateau. Some patients regain 2-5% of body weight in the first 8 to 12 weeks after switching due to the lower efficacy. Nausea typically improves.

Take your last tirzepatide dose, wait 7 days, then start semaglutide.

Switching between brand and compounded versions of the same medication:

No titration needed. If you're on Wegovy 2.4 mg, you can switch directly to compounded semaglutide 2.4 mg. Same for Zepbound to compounded tirzepatide.

The active ingredient is the same. Compounded versions may have different inactive ingredients (bacteriostatic water, B12, etc.), which rarely affects tolerance but can in sensitive individuals.

FAQ

Are Ozempic and Zepbound the same medication? No. Ozempic contains semaglutide (GLP-1 agonist). Zepbound contains tirzepatide (GLP-1 and GIP agonist). They have different active ingredients, different mechanisms, and different efficacy profiles.

Which is better for weight loss, Ozempic or Zepbound? Zepbound (tirzepatide) produces more weight loss on average: 20-22% vs 15-17% for Ozempic (semaglutide) at maximum doses. But "better" depends on tolerance, cost, and insurance coverage. Semaglutide is better tolerated by some patients and costs less.

Can I switch from Ozempic to Zepbound? Yes. Most providers start Zepbound at 2.5 mg weekly after stopping Ozempic, then titrate up every 4 weeks. Expect a nausea flare during the first 2 weeks and accelerated weight loss after 4 to 8 weeks.

Is Zepbound stronger than Ozempic? Yes, in terms of weight-loss efficacy. Tirzepatide 15 mg produces about 5 to 6 percentage points more weight loss than semaglutide 2.4 mg in head-to-head comparisons. The difference is driven by dual-receptor activation.

Do Ozempic and Zepbound have the same side effects? Mostly. Both cause nausea, vomiting, diarrhea, constipation, and delayed gastric emptying. Tirzepatide has slightly lower nausea rates (33% vs 44%) but higher reflux rates (9.4% vs 5.7%) in clinical trials.

Why is Zepbound more expensive than Ozempic? Tirzepatide is a newer medication with higher manufacturing costs and less generic competition. Brand-name Zepbound costs about 9% more than brand-name Wegovy. Compounded tirzepatide costs 40-60% more than compounded semaglutide due to raw material costs.

Can I take Ozempic and Zepbound together? No. Both medications activate GLP-1 receptors. Taking them together would overdose the GLP-1 pathway and dramatically increase side effect risk without additional benefit. Never combine GLP-1 medications.

Is compounded tirzepatide the same as Zepbound? Compounded tirzepatide contains the same active ingredient as Zepbound but is not FDA-approved and is not manufactured by Eli Lilly. It's prepared by a compounding pharmacy in response to an individual prescription. Quality and consistency may vary between compounding pharmacies.

Which causes more nausea, Ozempic or Zepbound? Ozempic (semaglutide) causes nausea in 44% of patients at the 2.4 mg dose. Zepbound (tirzepatide) causes nausea in 33% of patients at the 15 mg dose. Tirzepatide has lower overall nausea rates but more intense nausea during the first week after dose escalations.

Can I use Ozempic if Zepbound didn't work for me? Yes, but "didn't work" needs definition. If Zepbound caused intolerable nausea, switching to Ozempic may help. If Zepbound produced no weight loss despite good adherence, Ozempic is unlikely to work better since it's less effective. Discuss with your provider.

How long does it take to switch from Ozempic to Zepbound? Take your last Ozempic dose, wait 7 days, then start Zepbound at 2.5 mg. The 7-day gap allows semaglutide to clear (half-life is 7 days). You'll titrate Zepbound up every 4 weeks.

Does insurance cover both Ozempic and Zepbound? Coverage varies by plan. Most plans cover one or the other depending on your diagnosis. Ozempic is typically covered for type 2 diabetes. Zepbound is typically covered for obesity if your plan includes weight-loss medication benefits. Few plans cover both for the same patient.

Sources

1. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
4. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2): a randomised trial. The Lancet. 2021.
5. Nauck MA et al. GIP and GLP-1 receptor agonists in type 2 diabetes. Diabetes Care. 2022.
6. Frias JP et al. The sustained effects of a dual GIP and GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell Metabolism. 2017.
7. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. 2023.
8. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
9. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
10. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021.
11. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes (SURPASS-5). JAMA. 2022.
12. Lingvay I et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8). Diabetes Care. 2019.
13. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
14. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Zepbound, and Mounjaro are registered trademarks of Novo Nordisk and Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.